Objective: The aim of this study was to determine body composition, gynecological,
and obstetric data, sex hormones, and prolactin serum levels in pre- (PREW) and
postmenopausal women (PMW) with breast cancer (BC) and compare them with a
control group (CG) of healthy women.Methodology:BC patients
without treatment or use of hormone replacement therapy, orhormonal birth control, and without data of
metastasis were included. CG was matched for age, BMI, and menstrual cycle status. FSH, LH, E2,
progesterone, testosterone, and prolactin (PRL) were measured using
radioimmunoassay kits. Comparisons between BC and CG were made with “t”
tests, and with the Mann-Whitney U-test;χ2 test was used to
compare the qualitative variables between the groups. Results: Seventy-two patients with BC, and 74 CG women were evaluated. Both groups presented
overweight data, BMI (kg/mt2) = 27.21 ± 5.51 vs. 28.40 ±
4.66, p = ns, for BC patients and CG, respectively. In PREW, the age at
menarche was later in BC patients compared to the CG (13.3 ± 1.36 years vs.
12.41 ± 1.27 years, p = 0.005). The PMW with BC presented a higher age at
menarche and menopause compared to the women of the CG (13.51 ± 1.48 vs. 12.91
± 1.41, p = 0.09, and 49.03 ± 2.86 vs. 45.5 ± 8.78, p = 0.03, respectively).
PRL levels were significantly higher in PMW
with BC, in comparison with the CG; median and minimum and maximum values (min-max) were: 14.7 ng/mL (3.6-
References
[1]
Tamimi, R.M., Spiegelman, D., Smith-Warner, S.A., Wang, M., Pazaris, M., et al. (2016) Population Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer. American Journal of Epidemiolog, 184, 884-893. https://doi.org/10.1093/aje/kww145
[2]
Boyapati, S.M., Shu, X.O., Gao, Y.T., Dai, Q., Yu, H., et al. (2004) Correlation of Blood Sex Steroid Hormones with Body Size, Body Fat Distribution, and Other Known Risk Factors for Breast Cancer in Post-Menopausal Chinese Women. Cancer Causes & Control, 15, 305-311. https://doi.org/10.1023/B:CACO.0000024256.48104.50
[3]
Solanki, M. and Visscher, D. (2019) Pathology of Breast Cancer in the Last Half Century. Human Pathology, 95,137-148. https://doi.org/10.1016/j.humpath.2019.09.007
[4]
Brewer, H.R., Jones, M.E., Schoemaker, M.J., Ashworth, A. and Swerdlow, A.J. (2017) Family History and Risk of Breast Cancer: An Analysis Accounting for Family Structure. Breast Cancer Research and Treatment, 165, 193-200. https://doi.org/10.1007/s10549-017-4325-2
[5]
Rojas, K. and Stuckey, A. (2016) Breast Cancer Epidemiology and Risk Factors. Clinical Obstetrics and Gynecology, 59, 651-672. https://doi.org/10.1097/GRF.0000000000000239
[6]
Bardaweel, S.K., Akour, A.A., Al-Muhaissen, S., Al-Salamat, H.A. and Ammar, K. (2019) Oral Contraceptive and Breast Cancer: Do Benefits Outweigh the Risks? A Case—Control Study from Jordan. BMC Women’s Health, 19, Article No. 72. https://doi.org/10.1186/s12905-019-0770-x
[7]
Gompel, A. (2019) Hormones et cancers du sein. La Presse Médicale, 48, 1085-1091. https://doi.org/10.1016/j.lpm.2019.09.021
[8]
Clevenger, C.V., Furth, P.A., Hankinson, S.E. and Schuler L.A. (2003) The Role of Prolactin in Mammary Carcinoma. Endocrine Reviews, 24, 1-27. https://doi.org/10.1210/er.2001-0036
[9]
Yager, J.D. and Davidson, N.E. (2006) Estrogen Carcinogenesis in Breast Cancer. The New England Journal of Medicine, 354, 270-282. https://doi.org/10.1056/NEJMra050776
[10]
Kabuto, M., Akiba, S., Stevens, R.G., Neriishi, K. and Land, C.E. (2000) A Prospective Study of Estradiol and Breast Cancer in Japanese Women. Cancer Epidemiology, Biomarkers & Prevention, 9, 575-579.
[11]
Secreto, G., Recchione, C., Cavalleri, A., Miraglia, M. and Dati, V. (1983) Circulating Levels of Testosterone, 17 Beta-Oestradiol, Luteinising Hormone and Prolactin in Postmenopausal Breast Cancer Patients. British Journal of Cancer, 47, 269-275. https://doi.org/10.1038/bjc.1983.35
[12]
Hill, P., Garbaczewski, L. and Wynder, E.L. (1983) Testosterone in Breast Fluid. The Lancet, 321, 761. https://doi.org/10.1016/S0140-6736(83)92044-5
[13]
Kavarthapu, R., Anbazhagan, R. and Dufau, M.L. (2021) Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer. Cancers, 13, Article 4685. https://doi.org/10.3390/cancers13184685
[14]
Olsson, H., Alm, P., Aspegren, K., Gullberg, B., Jonsson, P.E., et al. (1990) Increased Plasma Prolactin Levels in a Group of Men with Breast Cancer—A Preliminary Study. Anticancer Research, 10, 59-62.
[15]
Coskun, U., Günel, N., Toruner, F.B., Sancak, B., Onuk, E. et al. (2003) Serum Leptin, Prolactin and Vascular Endothelial Growth Factor (VEGF) Levels in Patients with Breast Cancer. Neoplasma, 50, 41-46.
[16]
World Medical Association (2013) World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA, 310, 2191-2194. https://doi.org/10.1001/jama.2013.281053
[17]
Moreno-Frías, M., Chaudhari, S. and Huerta-Franco, M.R. (2017) Relationship of Food Craving Behavior with Body Mass Index and Body Composition in Reproductive age Females. Food and Nutrition Sciences, 8, 699-713. https://doi.org/10.4236/fns.2017.87049
[18]
Huerta, R., Dewailly, D., Decanter, C., Knochenhauer, E.S., Boots, L.R., et al. (2000) Adrenocortical Hyperresponsivity to Adrenocorticotropic Hormone: A Mechanism Favoring the Normal Production of Cortisol in 21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia, Fertility and Sterility, 74, 329-334. https://doi.org/10.1016/S0015-0282(00)00631-2
[19]
Blair, C.K., Wiggins, C.L., Nibbe, A.M., Storlie, C.B., Prossnitz, E.R. et al. (2019) Obesity and Survival among a Cohort of Breast Cancer Patients Is Partially Mediated by Tumor Characteristics. NPJ Breast Cancer, 5, Article No. 33. https://doi.org/10.1038/s41523-019-0128-4
[20]
Daling, J.R., Malone, K.E., Voigt, L.F., White, E. and Weiss, N.S. (1994) Risk of Breast Cancer among Young Women: Relationship to Induced Abortion. Journal of the National Cancer Institute, 86, 1584-1592. https://doi.org/10.1093/jnci/86.21.1584
[21]
Clevenger, C.V. and Rui, H. (2022) Breast Cancer, and Prolactin—New Mechanisms and Models. Endocrinology, 163, bqac122. https://doi.org/10.1210/endocr/bqac122
[22]
Love, R.R., Rose, D.R., Surawicz, T.S. and Newcomb, P.A. (1991) Prolactin and Growth Hormone Levels in Premenopausal Women with Breast Cancer and Healthy Women with a Strong Family History of Breast Cancer. Cancer, 68, 1401-1405. https://doi.org/10.1002/1097-0142(19910915)68:6<1401::AID-CNCR2820680637>3.0.CO;2-K
[23]
Manouchehri, E., Taghipour, A., Ghavami, V., Shandiz, F.H., Ebadi, A., et al. (2022) Menstrual and Reproductive Factors and Risk of Breast Cancer in Iranian Female Population: A Systematic Review and Meta-Analysis. International Journal of Preventive Medicine, 13, Article 26.
[24]
Schuler, L.A. and O’Leary, K.A. (2022) Prolactin: The Third Hormone in Breast Cancer. Frontiers in Endocrinology, 13, Article 910978. https://doi.org/10.3389/fendo.2022.910978
[25]
Aranha, A.F., Dos Anjos, L.G., Turri, J.A.O., Simoes, R.S., Maciel, G.A.R., et al. (2022) Impact of the Prolactin Levels in Breast Cancer: A Systematic Review and Meta-Analysis. Gynecological Endocrinology, 38, 385-390. https://doi.org/10.1080/09513590.2022.2047173
[26]
Hilton, H.N., Clarke, C.L. and Graham, J.D. (2018) Estrogen and Progesterone Signalling in the Normal Breast and Its Implications for Cancer Development. Molecular and Cellular Endocrinology, 466, 2-14. https://doi.org/10.1016/j.mce.2017.08.011
[27]
Zinger, M., McFarland, M. and Ben-Jonathan, N. (2003) Prolactin Expression and Secretion by Human Breast Glandular and Adipose Tissue Explants. The Journal of Clinical Endocrinology & Metabolism, 88, 689-696. https://doi.org/10.1210/jc.2002-021255
